A Study of the Impact of Treatment Response to Direct Acting Antivirals on Serum Lipid Profile in Egyptian Patients with Chronic HCV Infection
Authors:
Open Access
- 1 September 2019
- journal article
- research article
- Published by Egyptian Knowledge Bank in The Medical Journal of Cairo University
- Vol. 87 (September) , 3175-3180
Abstract
Background: Hepatitis C virus infection is a major etio-logical factor for liver cirrhosis, steatosis, and hepatocellular carcinoma. HCV is known to be closely related and associated with host and lipid metabolism.Aim of Study: This study aimed at studying the changes in serum lipid profile with INF-free treatment regimens in chronic HCV infection.Patients and Methods: This prospective observational cohort study was carried out on 301 chronic HCV-infected patients, who had fulfilled the inclusion & exclusion criteria and treated according to the National Committee of Control of Viral Hepatitis (NCCVH) Treatment Protocol, updated in December 2016, and completed their course of treatment and follow-up. They were divided into two groups. Group I included 264 patients, who achieved SVR and Group II included 37 patients who did not achieve SVR. Patients underwent additional investigations in the form of 12h fasting serum lipids profile (mg/dl) including: Serum cholesterol, serum triglycerides, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL). These tests were done before starting treatment (baseline), at the end of treatment.Results: There was a statistically significant difference between responder and non-responder groups as regard baseline cholesterol (p=0.001), LDL (p=0.001), HDL (p=0.026) and triglycerides levels (p=0.016). These lipid parameters increased significantly over the course of the therapy and continued to be increased after treatment discontinuation in responders; while they showed non-significant changes in non-responders.Conclusions: Viral eradication was associated with in-creased serum cholesterol, TG & LDL levels, which continued to be elevated after discontinuation of therapy.Keywords
This publication has 13 references indexed in Scilit:
- Worsening of serum lipid profile after direct acting antiviral treatmentJournal of Hepatology, 2017
- Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7Gastroenterology, 2017
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013The Lancet, 2016
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1New England Journal of Medicine, 2015
- Difficult‐to‐cure populations with chronic hepatitis c: Vanishing in the direct‐acting antiviral era?Hepatology, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patientsHepatology, 2014
- Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infectionAntiviral Research, 2014
- Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1Journal of Medical Virology, 2012